首页> 外文期刊>Nucleic acids research >The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY
【24h】

The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY

机译:2020年的Iuphar / BPS Pharmacology指南:延长免疫药物含量并向疟疾药理学引入Iuphar / MMV指南

获取原文
       

摘要

The IUPHAR/BPS Guide to PHARMACOLOGY (www.guidetopharmacology.org) is an open-access, expert-curated database of molecular interactions between ligands and their targets. We describe significant updates made over the seven releases during the last two years. The database is notably enhanced through the continued linking of relevant pharmacology with key immunological data types as part of the IUPHAR Guide to IMMUNOPHARMACOLOGY (www.guidetoimmunopharmacology.org) and by a major new extension, the IUPHAR/MMV Guide to Malaria PHARMACOLOGY (www.guidetomalariapharmacology.org). The latter has been constructed in partnership with the Medicines for Malaria Venture, an organization dedicated to identifying, developing and delivering new antimalarial therapies that are both effective and affordable. This is in response to the global challenge of over 200 million cases of malaria and 400 000 deaths worldwide, with the majority in the WHO Africa Region. It provides new pharmacological content, including molecular targets in the malaria parasite, interaction data for ligands with antimalarial activity, and establishes curation of data from screening assays, used routinely in antimalarial drug discovery, against the whole organism. A dedicated portal has been developed to provide quick and focused access to these new data.
机译:Iuphar / BPS药理学指南(www.guidetopharmacology.org)是配体与其目标之间的开放式,专家策划数据库的分子相互作用。我们在过去两年中描述了在七个版本上进行的重大更新。通过与关键免疫数据类型的相关药物类型的持续联系,作为Iuphar指南的一部分和疟疾药理学的重大新延伸,通过持续的关键免疫数据类型的持续连接,通过持续的关键免疫数据类型进行了显着提高了数据库。 GuideToMalariaPharmacology.org)。后者已与疟疾企业的药物合作,该组织致力于识别,开发和提供有效且价格实惠的新的抗疟疾疗法。这是对世界卫生组织非洲地区的大多数人在全球范围内拥有超过2亿例疟疾和400 000人死亡的全球挑战。它提供了新的药理学含量,包括疟疾寄生虫中的分子靶标,具有抗疟疾活性的配体的相互作用数据,并建立来自筛选测定的数据策析,常规用于抗疟药的药物发现,对抗整个生物。已开发专用门户以提供对这些新数据的快速和专注的访问。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号